Evidence map›Paper›PMID 40035286›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2025

Rational design, synthesis, and molecular modelling insights of dual DNA binders/DHFR inhibitors bearing arylidene-hydrazinyl-1,3-thiazole scaffold with apoptotic and anti-migratory potential in breast MCF-7 cancer cells.

Marwa H El-Wakil, Rasha A Ghazala, Hadeel A El-Dershaby, Danuta Drozdowska, Agnieszka Wróbel-Tałałaj, Cezary Parzych, Artur Ratkiewicz, Beata Kolesińska, Heba A Abd El-Razik, Farid S G Soliman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marwa H El-WakilDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Rasha A GhazalaDepartment of Medical Biochemistry, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Hadeel A El-DershabyDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Danuta DrozdowskaDepartment of Organic Chemistry, Medical University of Bialystok, Bialystok, Poland.
Agnieszka Wróbel-TałałajDepartment of Organic Chemistry, Medical University of Bialystok, Bialystok, Poland.
Cezary ParzychDepartment of Physical Chemistry, University of Bialystok, Institute of Chemistry, Bialystok, Poland.
Artur RatkiewiczDepartment of Physical Chemistry, University of Bialystok, Institute of Chemistry, Bialystok, Poland.
Beata KolesińskaInstitute of Organic Chemistry, Lodz University of Technology, Lodz, Poland.
Heba A Abd El-RazikDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Farid S G SolimanDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In light of searching for new breast cancer therapies, DNA-targeted small molecules were rationally designed to simultaneously bind DNA and inhibit human dihydrofolate reductase (

Indexed as

Antineoplastic AgentsApoptosisBreast NeoplasmsDNADrug DesignFolic Acid AntagonistsTetrahydrofolate DehydrogenaseThiazolesCell MovementCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorFemaleHumansMCF-7 CellsModels, MolecularAntineoplastic AgentsDNAFolic Acid AntagonistsTetrahydrofolate DehydrogenaseThiazolesanti-tumorDHFRDNA bindersmolecular modellingThiazoles

Identifiers

PMID40035286
PMCPMC11881662

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.